Please enable Javascript
Multiple Myeloma Awareness
Video Answers Common Questions About Intravenous Immunoglobulin Treatment
Dustin Samples
Multiple Myeloma
|
March 27, 2023
The HealthTree Foundation for Multiple Myeloma interviews Dr. Urvi Shah about IVIG.
Read More
Cytogenetics Offers Insight Into MM Disease Course, Risk, and Outcomes
Dustin Samples
Multiple Myeloma
|
March 27, 2023
Fluorescence in situ hybridization can detect genetic abnormalities that allow stratification of disease risk.
Read More
Talquetamab Performs Well in NEJM Study of Adverse Events and Responses
Dustin Samples
Multiple Myeloma
|
March 27, 2023
Only 2 patients experienced adverse events higher than grade 1 or 2, and response rates were high.
Read More
Review Article Outlines Common Adverse Events and Treatments for Relapsed/Refractory MM
Dustin Samples
Multiple Myeloma
|
March 20, 2023
Toxicity- and disease-related adverse outcomes can affect the quality of life in this high-exposure population.
Read More
Higher Incidence of Adverse Outcomes Found in Marginalized Racial/Ethnic Patients With Cancer
Dustin Samples
Multiple Myeloma
|
March 20, 2023
Non-Hispanic Black and Hispanic patients reported worse mental health and poorer sleep than their non-Hispanic White peers.
Read More
Bispecific Antibodies Are Associated With Infection in Patients With Relapsed/Refractory MM
Dustin Samples
Multiple Myeloma
|
March 20, 2023
Half of all patients in a synthesized analysis developed infections, and a quarter developed grade III/IV infections.
Read More
Addressing Barriers to Multiple Myeloma Care in Elderly Patient-Caregiver Dyads
Dustin Samples
Multiple Myeloma
|
March 13, 2023
Survey respondents described transportation, information, and scheduling barriers to treatment.
Read More
Review Article Compiles Useful Information on MM Targeted Therapies
Dustin Samples
Multiple Myeloma
|
March 13, 2023
With many new targeted drugs available, nurses are under pressure to keep up with administration and toxicity profiles.
Read More
New Algorithm Proposed for Pneumocystis Jirovecii Pneumonia Prevention in MM
Dustin Samples
Multiple Myeloma
|
March 13, 2023
Nurses at the Huntsman Cancer Institute believe their algorithm successfully predicts PJP and decreases CD4 monitoring costs.
Read More
Managing Oncologic Emergencies in Multiple Myeloma Treatment
Dustin Samples
Multiple Myeloma
|
March 8, 2023
Myelosuppression, bone disease, and acute renal failure are discussed in this review, and treatment options are provided.
Read More
A Multiple Myeloma Survivor Talks Treatments With Leading Physicians
Dustin Samples
Multiple Myeloma
|
March 8, 2023
Discussing results from ASH, Cindy Chmielewski from The Patient Story spoke with Drs. Caitlin Costello and Sagar Lonial.
Read More
Eliminating Post-Injection Monitoring for Subcutaneous Daratumumab
Dustin Samples
Multiple Myeloma
|
March 8, 2023
It may be possible to eliminate the monitoring period after subcutaneous daratumumab and increase chair availability.
Read More
New Drug Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
Dustin Samples
Multiple Myeloma
|
February 28, 2023
The new bispecific antibody boasted an overall response rate of more than 60 percent and has received accelerated approval.
Read More
Assessment and Treatment of Distress, Fatigue, and Sexual Dysfunction in Patients With Multiple Myeloma
Dustin Samples
Multiple Myeloma
|
February 28, 2023
Recognizing and managing distress, fatigue, and sexual dysfunction in patients with MM can be difficult.
Read More
Updated Recommendations on Bone Health, Pain, and Mobility in Patients With Multiple Myeloma
Dustin Samples
Multiple Myeloma
|
February 28, 2023
Nurses should assess patients for bone pain and mobility at each encounter and should consider implementing an activity plan.
Read More
Advertisement
Advertisement